Migration of multiple sclerosis lymphocytes through brain endothelium

Area of Science:

• Neuroimmunology
• Cellular and Molecular Neuroscience

Background:

• T-lymphocyte migration across the blood-brain barrier is critical for lesion development in multiple sclerosis (MS).
• Understanding the mechanisms of this migration is key to developing effective MS therapies.

Purpose of the Study:

• To quantify T-lymphocyte migration in MS patients using an in vitro blood-brain barrier model.
• To identify the molecular mediators, specifically chemokines and matrix metalloproteinases, involved in MS T-lymphocyte migration.

Main Methods:

• Development of an in vitro model using Boyden chambers with human brain microvascular endothelial cells.
• Assessment of lymphocyte migration rates from MS patients and healthy controls.
• Quantification of chemokine production (MCP-1, IL-8) and inhibition studies using monoclonal antibodies and MMP inhibitors.

Main Results:

• Lymphocyte migration rates were significantly higher in patients with active MS compared to healthy controls and inactive MS patients.
• Monocyte chemoattractant protein 1 (MCP-1) and Interleukin-8 (IL-8) were identified as key chemokines produced by brain endothelial cells.
• Anti-MCP-1 antibodies reduced MS lymphocyte migration by 60%, and a matrix metalloproteinase inhibitor (TIMP-1) reduced it by 50%.

Conclusions:

• MS T-lymphocyte migration across the brain endothelium is elevated, particularly in active disease.
• This enhanced migration is significantly dependent on the chemokine MCP-1 and matrix metalloproteinases.
• These findings highlight MCP-1 and matrix metalloproteinases as potential therapeutic targets for reducing T-cell infiltration in MS.